Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

Fourth quarter 2023 revenues increased 1% to $3.43 billion versus fourth quarter 2022; excluding RonapreveTM, revenues increased 14%Full year 2023 revenues increased 8% to $13.12 billion versus full...

Related Keywords

Rensselaer ,New York ,United States ,West Virginia ,Massachusetts ,Tarrytown ,Japan ,America ,American ,Christina Chan ,Novarti Ilaris ,Bryan Crowe ,Sanofi Immuno ,States Sanofi ,Leonards Schleifer ,Bob Landry ,Roberte Landry ,Company Rensselaer ,Regeneron Pharmaceuticals Inc ,Business Development Updates ,European Society For Medical Oncology Immuno ,Biocon ,Nasdaq ,European Union ,Regeneron Genetics Center ,United States Centers For Medicare Medicaid Services ,Checkmate Pharmaceuticals Inc ,Corporate Affairs ,United States District Court ,Linkedin ,Biocon Biologics Inc ,American Society Of Hematology ,Japan Ministry Of Health ,Viatris Inc ,Board Co ,European Commission ,Oncology Esmo Io Congress ,Alnylam Pharmaceuticals Inc ,Mitsubishi Tanabe Pharma Corporation ,Mylan Pharmaceuticals Inc ,Exchange Commission ,Drug Administration ,Regeneron Pharmaceuticals ,Board Co Chair ,Chief Executive Officer ,Chief Financial Officer ,Executive Vice President ,United States Centers ,Medicaid Services ,Healthcare Common Procedure Coding System ,Biologics License Application ,American Society ,Annual Meeting ,European Society ,Medical Oncology Immuno ,Breakthrough Therapy ,Business Development ,Biocon Biologics ,Northern District ,Dow Jones Sustainability World Index ,Dow Jones Sustainability North America Index ,Effective July ,Alnylam Pharmaceuticals ,Checkmate Pharmaceuticals ,Sanofi Immuno Oncology ,Accepted Accounting Principles ,Regeneron Genetics ,Looking Statements ,Product Candidates ,Total Sales ,Markets ,